ABSTRACT
A moxibustion device with the functions of auricular fumigation moxibustion and heat-sensitive moxibustion is designed. The smoke of the ignited moxa stick is used for the fumigation moxibustion at the external auditory canal, while the heat generated works on Dazhui (GV 14) for heat-sensitive moxibustion. The device consists of five parts, i.e. combustion chamber, smoke pipe, smoke processing chamber, power module and connector. It solves the limitations such as unpleasant experience in treatment, unfavorable temperature control, easy scalding and excessive manual dependence induced by usual fumigation moxibustion and during heat-sensitive moxibustion. This moxibustion device may improve the safety and convenience when delivering the treatment with fumigation moxibustion and heat-sensitive moxibustion, as well as the work efficiency of medical staff.
Subject(s)
Humans , Moxibustion , Hot Temperature , Fumigation , Smoke , TemperatureABSTRACT
An automatic ash-removal heat-sensitive moxibustion device was developed, which could keep relatively constant temperature of heat-sensitive moxibustion, and realize the automatic ignition and automatic ash removal of moxa sticks during heat-sensitive moxibustion. The automatic ash-removal heat-sensitive moxibustion device comprises a bracket and a moxibustion box fixed on the top of the bracket; the bracket is composed of a base and a movable telescopic arm. This device can solve the problems of temperature instability, moxa ash blocking heat transfer and moxa ash falling during heat-sensitive moxibustion, avoiding the scalding caused by moxa ash falling, and reduce the workload of medical staff.
Subject(s)
Humans , Hot Temperature , Moxibustion , TemperatureABSTRACT
Objective· To investigate the relationship between pathological myopia and classification of vitreoretinal interface features using enhanced vitreous imaging optical coherence tomography (EVI-OCT). Methods · High myopia patients were included from 2015 to 2016. All participants underwent standardized medical interviews and ophthalmic examination. Results · The included eyes were divided into two groups of pathological myopia and simple high myopia based on myopic macular degeneration observed on fundus photography . There were four types of vitreoretinal interface changes demonstrated on EVI-OCT scans in included eyes: Type1, posterior precortical vitreous pockets (PPVP), Type2, partial posterior vitreous detachment with vitreous adhesion (VA), Type 3, epiretinal membrane (ERM), and Type 4, no traction (NT). Pathological myopia was mostly detected in VA, ERM, and NT groups. Conclusion · EVI-OCT was able to demonstrate the early changes of vitreoretinal interface in high myopia eyes. Vitreous adhesions and traction detected by OCT may facilitate the occurrence of pathological myopia.
ABSTRACT
Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years old. Vascular endothelial growth factor (VEGF) plays a critical role in the development of wet AMD. At present, the main treatment is monoclonal antibodies against VEGF, but the maintenance time is short, and it requires frequent and repeated treatment. Recently with the fast development of gene therapy, soluble VEGF receptor -1 (sFlt-1), which may act as one of the biomarkers of AMD, is gaining more attention. sFlt-1 is the unique endogenous VEGF inhibitor. With the development of AMD, serum sFlt-1 decreases markedly. This article reviewed the molecular structure and pathophysiological function of sFlt-1, its role in the advance of AMD, and the preclinical studies as well as clinical studies about it.
ABSTRACT
Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years old. Vascular endothelial growth factor (VEGF) plays a critical role in the development of wet AMD. At present, the main treatment is monoclonal antibodies against VEGF, but the maintenance time is short, and it requires frequent and repeated treatment. Recently with the fast development of gene therapy, soluble VEGF receptor -1 (sFlt-1), which may act as one of the biomarkers of AMD, is gaining more attention. sFlt-1 is the unique endogenous VEGF inhibitor. With the development of AMD, serum sFlt-1 decreases markedly. This article reviewed the molecular structure and pathophysiological function of sFlt-1, its role in the advance of AMD, and the preclinical studies as well as clinical studies about it.